NASDAQ:CTSO - Cytosorbents Stock Price, Price Target & More

$7.80 +0.05 (+0.65 %)
(As of 04/26/2018 09:36 AM ET)
Previous Close$7.75
Today's Range$7.80 - $7.80
52-Week Range$3.30 - $8.35
Volume500 shs
Average Volume179,932 shs
Market Capitalization$221.04 million
P/E Ratio-24.22
Dividend YieldN/A
Beta-0.09

About Cytosorbents (NASDAQ:CTSO)

Cytosorbents logoCytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. The company also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, it is developing CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, the company is developing BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. It has collaboration with Aferetica srl to develop PerLife ex-vivo organ perfusion system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is headquartered in Monmouth Junction, New Jersey.

Receive CTSO News and Ratings via Email

Sign-up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CTSO
CUSIPN/A
Phone732-329-8885

Debt

Debt-to-Equity Ratio0.58%
Current Ratio2.64%
Quick Ratio2.54%

Price-To-Earnings

Trailing P/E Ratio-24.22
Forward P/E Ratio-16.60
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.15 million
Price / Sales15.17
Cash FlowN/A
Price / CashN/A
Book Value$0.36 per share
Price / Book21.67

Profitability

EPS (Most Recent Fiscal Year)($0.32)
Net Income$-8,460,000.00
Net Margins-52.08%
Return on Equity-118.07%
Return on Assets-40.15%

Miscellaneous

Employees84
Outstanding Shares29,470,000

How to Become a New Pot Stock Millionaire

Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions

What is Cytosorbents' stock symbol?

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

How were Cytosorbents' earnings last quarter?

Cytosorbents Co. (NASDAQ:CTSO) released its quarterly earnings data on Thursday, March, 8th. The medical research company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.02. The medical research company earned $4.65 million during the quarter, compared to the consensus estimate of $4.56 million. Cytosorbents had a negative return on equity of 118.07% and a negative net margin of 52.08%. View Cytosorbents' Earnings History.

When is Cytosorbents' next earnings date?

Cytosorbents is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for Cytosorbents.

What price target have analysts set for CTSO?

5 brokerages have issued 12 month price objectives for Cytosorbents' shares. Their forecasts range from $9.00 to $14.00. On average, they expect Cytosorbents' stock price to reach $11.05 in the next twelve months. View Analyst Ratings for Cytosorbents.

Who are some of Cytosorbents' key competitors?

Who are Cytosorbents' key executives?

Cytosorbents' management team includes the folowing people:
  • Dr. Phillip P. Chan M.D., Ph.D., CEO, Pres & Director (Age 48)
  • Ms. Kathleen P. Bloch MBA, CPA, CFO & Sec. (Age 63)
  • Mr. Vincent J. Capponi MS, Chief Operating Officer (Age 60)
  • Dr. Robert H. Bartlett M.D., Co-Chairman of Cardiac Surgery Advisory Board & Consultant (Age 79)
  • Dr. Christian Steiner M.D., VP of Sales & Marketing

Has Cytosorbents been receiving favorable news coverage?

News coverage about CTSO stock has been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cytosorbents earned a daily sentiment score of 0.15 on Accern's scale. They also assigned press coverage about the medical research company an impact score of 45.34 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Cytosorbents?

Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytosorbents' stock price today?

One share of CTSO stock can currently be purchased for approximately $7.80.

How big of a company is Cytosorbents?

Cytosorbents has a market capitalization of $221.04 million and generates $15.15 million in revenue each year. The medical research company earns $-8,460,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Cytosorbents employs 84 workers across the globe.

How can I contact Cytosorbents?

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected]


MarketBeat Community Rating for Cytosorbents (CTSO)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  269 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  357
MarketBeat's community ratings are surveys of what our community members think about Cytosorbents and other stocks. Vote "Outperform" if you believe CTSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTSO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cytosorbents (NASDAQ:CTSO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Cytosorbents in the last 12 months. Their average twelve-month price target is $11.05, suggesting that the stock has a possible upside of 41.67%. The high price target for CTSO is $14.00 and the low price target for CTSO is $9.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.05$11.05$10.65$10.45
Price Target Upside: 41.67% upside39.87% upside37.95% upside72.73% upside

Cytosorbents (NASDAQ:CTSO) Consensus Price Target History

Price Target History for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ:CTSO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/24/2018Maxim GroupSet Price TargetBuy$12.00HighView Rating Details
3/9/2018HC WainwrightSet Price TargetBuy$14.00MediumView Rating Details
3/8/2018CowenSet Price TargetBuy$9.00MediumView Rating Details
1/25/2018B. RileyReiterated RatingBuy$11.25LowView Rating Details
7/25/2017AegisReiterated RatingBuy$9.00HighView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$24.00N/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Cytosorbents (NASDAQ:CTSO) Earnings History and Estimates Chart

Earnings by Quarter for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ:CTSO) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.09)($0.09)($0.09)
Q2 20181($0.11)($0.11)($0.11)

Cytosorbents (NASDAQ CTSO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018N/AView Earnings Details
3/8/2018Q4 2017($0.10)($0.12)$4.56 million$4.65 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.07)($0.07)$3.67 million$3.45 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.06)($0.04)$3.29 million$3.57 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.11)($0.05)$2.99 million$3.11 millionViewListenView Earnings Details
3/3/2017Q4 2016($0.10)($0.16)$2.59 million$3.08 millionViewN/AView Earnings Details
11/7/2016Q3($0.11)($0.11)$2.35 million$2.14 millionViewListenView Earnings Details
8/9/2016Q216($0.09)($0.12)$2.18 million$1.90 millionViewN/AView Earnings Details
5/9/2016Q116($0.10)($0.08)$1.73 million$1.80 millionViewN/AView Earnings Details
3/9/2016Q415($0.08)($0.08)$1.51 million$1.76 millionViewN/AView Earnings Details
11/13/2015Q315($0.10)($0.11)$1.26 million$1.30 millionViewListenView Earnings Details
8/13/2015Q215($0.11)$0.05$0.92 million$0.96 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.11)$0.80 million$0.72 millionViewListenView Earnings Details
11/12/2014Q3 2014($0.25)($0.25)$1.28 million$1.16 millionViewN/AView Earnings Details
8/12/2014Q2 2014($0.01)($0.01)$1.13 million$1.03 millionViewN/AView Earnings Details
5/14/2014Q1 2014($0.25)($0.25)$1.02 million$1.06 millionViewN/AView Earnings Details
3/31/2014Q4 2013($0.01)($0.01)$8.34 million$0.88 millionViewN/AView Earnings Details
11/6/2013Q3 2013($0.25)($0.25)$0.70 million$0.88 millionViewN/AView Earnings Details
8/14/2013Q2 2013($0.25)($0.25)$0.29 millionViewN/AView Earnings Details
5/16/2013Q1 2013($0.25)$0.85 million$0.37 millionViewN/AView Earnings Details
4/3/2013Q4 2012($0.25)ViewN/AView Earnings Details
11/21/2012Q3 2012($0.25)($0.25)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cytosorbents (NASDAQ:CTSO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cytosorbents (NASDAQ CTSO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 10.85%
Insider Trading History for Cytosorbents (NASDAQ:CTSO)
Institutional Ownership by Quarter for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ CTSO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/17/2018Kathleen P BlochCFOSell120$8.25$990.00253,424View SEC Filing  
3/15/2018Kathleen P BlochCFOSell11,176$8.25$92,202.00261,246View SEC Filing  
3/13/2018Kathleen P BlochCFOSell1,104$8.25$9,108.00251,174View SEC Filing  
2/21/2018Kathleen P BlochCFOSell10,000$8.00$80,000.00268,870View SEC Filing  
1/12/2018Kathleen P BlochCFOSell12,400$7.75$96,100.00241,038View SEC Filing  
1/8/2018Kathleen P BlochCFOSell32,400$7.30$236,520.00248,638View SEC Filing  
11/27/2017Vincent CapponiCOOSell4,000$7.00$28,000.00271,062View SEC Filing  
6/9/2017Eric R MortensenInsiderBuy2,500$4.04$10,100.002,500View SEC Filing  
6/9/2017Michael G. BatorDirectorBuy1,500$4.12$6,180.00View SEC Filing  
6/8/2017Phillip P. ChanInsiderBuy3,700$4.00$14,800.00View SEC Filing  
6/8/2017Vincent CapponiCOOBuy2,500$4.00$10,000.00View SEC Filing  
6/5/2017Phillip P. ChanInsiderBuy6,300$4.00$25,200.00View SEC Filing  
5/15/2017Kathleen P. BlochCFOBuy1,000$4.34$4,340.00View SEC Filing  
12/9/2016Phillip P. ChanInsiderBuy4,600$5.40$24,840.00View SEC Filing  
12/6/2016Kathleen P BlochCFOBuy1,000$4.83$4,830.00122,325View SEC Filing  
8/24/2016Phillip P ChanInsiderBuy5,000$4.89$24,450.00121,648View SEC Filing  
6/7/2016Michael G BatorDirectorBuy3,000$4.88$14,640.003,000View SEC Filing  
10/29/2015Vincent CapponiCOOSell4,000$7.50$30,000.0016,724View SEC Filing  
10/15/2015Al KrausDirectorSell6,774$6.22$42,134.2855,746View SEC Filing  
10/8/2015Al KrausDirectorSell10,000$6.39$63,900.0055,746View SEC Filing  
10/1/2015Al KrausDirectorSell10,000$6.26$62,600.0055,746View SEC Filing  
9/24/2015Al KrausDirectorSell10,000$6.44$64,400.0055,746View SEC Filing  
9/17/2015Al KrausDirectorSell10,000$6.64$66,400.0055,746View SEC Filing  
9/10/2015Al KrausDirectorSell10,000$7.26$72,600.0055,746View SEC Filing  
9/3/2015Al KrausDirectorSell10,000$7.26$72,600.0055,746View SEC Filing  
8/27/2015Al KrausDirectorSell10,000$6.39$63,900.0055,746View SEC Filing  
8/20/2015Al KrausDirectorSell10,000$7.26$72,600.0055,746View SEC Filing  
8/13/2015Al KrausDirectorSell10,000$6.26$62,600.00View SEC Filing  
7/23/2015Al KrausDirectorSell10,000$6.28$62,800.00View SEC Filing  
7/16/2015Al KrausDirectorSell10,000$6.33$63,300.00View SEC Filing  
7/9/2015Al KrausDirectorSell10,000$5.98$59,800.00View SEC Filing  
7/2/2015Al KrausDirectorSell10,000$6.29$62,900.00View SEC Filing  
6/25/2015Al KrausDirectorSell13,205$7.33$96,792.65View SEC Filing  
6/18/2015Al KrausDirectorSell10,000$5.78$57,800.00View SEC Filing  
6/11/2015Al KrausDirectorSell10,000$6.29$62,900.00View SEC Filing  
6/4/2015Al KrausDirectorSell10,000$6.30$63,000.00View SEC Filing  
5/28/2015Al KrausDirectorSell10,000$6.32$63,200.00View SEC Filing  
11/17/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
11/10/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
11/3/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
10/27/2014Al KrausDirectorSell100,000$0.24$24,000.00View SEC Filing  
10/10/2014James T GuntonDirectorSell1,240,762$0.24$297,782.88View SEC Filing  
10/6/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/29/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/25/2014Al KrausDirectorSell41,500$0.23$9,545.00View SEC Filing  
9/22/2014Al KrausDirectorSell8,500$0.23$1,955.00View SEC Filing  
9/15/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/12/2014James T GuntonDirectorSell30,450$0.24$7,308.00View SEC Filing  
9/8/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/5/2014James T GuntonDirectorSell100,000$0.24$24,000.00View SEC Filing  
9/2/2014Al KrausDirectorSell50,000$0.25$12,500.00View SEC Filing  
9/2/2014Kathleen P BlochCFOBuy65,000$0.23$14,950.00View SEC Filing  
8/28/2014James T GuntonDirectorSell214,387$0.24$51,452.88View SEC Filing  
8/27/2014James T GuntonDirectorSell1,360,000$0.24$326,400.00View SEC Filing  
8/25/2014Al KrausDirectorSell100,000$0.25$25,000.00View SEC Filing  
8/18/2014Al KrausDirectorSell100,000$0.27$27,000.00View SEC Filing  
8/11/2014Al KrausDirectorSell100,000$0.28$28,000.00View SEC Filing  
8/4/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/21/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/10/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/7/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
6/23/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
6/18/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
5/20/2014Kathleen P BlochCFOBuy110,000$0.24$26,400.00View SEC Filing  
9/4/2012Phillip P ChanCEOBuy190,000$0.13$24,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cytosorbents (NASDAQ CTSO) News Headlines

Source:
DateHeadline
$4.56 Million in Sales Expected for Cytosorbents Co. (CTSO) This Quarter$4.56 Million in Sales Expected for Cytosorbents Co. (CTSO) This Quarter
www.americanbankingnews.com - April 26 at 2:36 AM
Cytosorbents Co. (CTSO) Expected to Post Earnings of -$0.13 Per ShareCytosorbents Co. (CTSO) Expected to Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - April 24 at 3:10 PM
Cytosorbents (CTSO) PT Set at $12.00 by Maxim GroupCytosorbents (CTSO) PT Set at $12.00 by Maxim Group
www.americanbankingnews.com - April 24 at 12:14 PM
CytoSorbents Enrolls First Patient into Pivotal US REFRESH 2-AKI Trial Using CytoSorb® During Complex Cardiac ...CytoSorbents Enrolls First Patient into Pivotal US REFRESH 2-AKI Trial Using CytoSorb® During Complex Cardiac ...
www.prnewswire.com - April 24 at 8:46 AM
BRIEF-Cytosorbents Enrolls First Patient Into Pivotal US Refresh 2-AKI TrialBRIEF-Cytosorbents Enrolls First Patient Into Pivotal US Refresh 2-AKI Trial
www.reuters.com - April 24 at 8:46 AM
CytoSorbents Enrolls First Patient into Pivotal U.S. REFRESH 2-AKI Trial Using CytoSorb® During Complex Cardiac SurgeryCytoSorbents Enrolls First Patient into Pivotal U.S. REFRESH 2-AKI Trial Using CytoSorb® During Complex Cardiac Surgery
finance.yahoo.com - April 24 at 8:46 AM
Form 4 Cytosorbents Corp For: Apr 17 Filed by: BLOCH KATHLEEN P.Form 4 Cytosorbents Corp For: Apr 17 Filed by: BLOCH KATHLEEN P.
www.streetinsider.com - April 19 at 8:46 AM
Maxim Group Analysts Give Cytosorbents (CTSO) a $10.00 Price TargetMaxim Group Analysts Give Cytosorbents (CTSO) a $10.00 Price Target
www.americanbankingnews.com - April 17 at 10:21 PM
CytoSorbents to Meet With European Investors at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo and in Meetings in Frankfurt, Geneva and ZurichCytoSorbents to Meet With European Investors at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo and in Meetings in Frankfurt, Geneva and Zurich
finance.yahoo.com - April 17 at 9:08 AM
Cytosorbents (CTSO) Earns Buy Rating from B. RileyCytosorbents (CTSO) Earns Buy Rating from B. Riley
www.americanbankingnews.com - April 14 at 1:27 PM
Cytosorbents (CTSO) Given a $13.00 Price Target by HC Wainwright AnalystsCytosorbents (CTSO) Given a $13.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 12 at 8:29 PM
Cytosorbents (CTSO) PT Raised to $12.00 at Maxim GroupCytosorbents (CTSO) PT Raised to $12.00 at Maxim Group
www.americanbankingnews.com - April 12 at 8:29 PM
Cytosorbents (CTSO) Rating Increased to Hold at ValuEngineCytosorbents (CTSO) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - April 9 at 11:35 AM
Cytosorbents Co. (CTSO) Expected to Post Quarterly Sales of $4.56 MillionCytosorbents Co. (CTSO) Expected to Post Quarterly Sales of $4.56 Million
www.americanbankingnews.com - April 9 at 2:20 AM
Cytosorbents (CTSO) Downgraded to "Sell" at ValuEngineCytosorbents (CTSO) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - April 8 at 12:54 PM
 Analysts Anticipate Cytosorbents Co. (CTSO) to Announce -$0.13 Earnings Per Share Analysts Anticipate Cytosorbents Co. (CTSO) to Announce -$0.13 Earnings Per Share
www.americanbankingnews.com - April 7 at 5:22 PM
Form 4 Cytosorbents Corp For: Feb 21 Filed by: BLOCH KATHLEEN P.Form 4 Cytosorbents Corp For: Feb 21 Filed by: BLOCH KATHLEEN P.
www.streetinsider.com - April 6 at 9:00 AM
Cytosorbents Co. (CTSO) CFO Kathleen P. Bloch Sells 10,000 SharesCytosorbents Co. (CTSO) CFO Kathleen P. Bloch Sells 10,000 Shares
www.americanbankingnews.com - April 5 at 10:20 PM
Cytosorbents Co. (CTSO) Receives Consensus Recommendation of "Buy" from AnalystsCytosorbents Co. (CTSO) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 5 at 1:37 AM
CytoSorbents Refinances Existing Debt with New $15 Million Debt Facility with Bridge BankCytoSorbents Refinances Existing Debt with New $15 Million Debt Facility with Bridge Bank
finance.yahoo.com - April 4 at 8:51 AM
ValuEngine Upgrades Cytosorbents (CTSO) to BuyValuEngine Upgrades Cytosorbents (CTSO) to Buy
www.americanbankingnews.com - April 4 at 12:02 AM
Cytosorbents (CTSO) Upgraded at ValuEngineCytosorbents (CTSO) Upgraded at ValuEngine
www.americanbankingnews.com - March 30 at 1:04 PM
Cytosorbents (CTSO) Stock Rating Reaffirmed by HC WainwrightCytosorbents (CTSO) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - March 29 at 10:16 PM
-$0.13 EPS Expected for Cytosorbents Corp (CTSO) This Quarter-$0.13 EPS Expected for Cytosorbents Corp (CTSO) This Quarter
www.americanbankingnews.com - March 21 at 5:18 PM
CTSO: Q4 2017 Update: Q4 / FY Product Sales +64% / 63%, Product Margin Jumps 900bp. FDA Pivotal Study UnderwayCTSO: Q4 2017 Update: Q4 / FY Product Sales +64% / 63%, Product Margin Jumps 900bp. FDA Pivotal Study Underway
finance.yahoo.com - March 19 at 4:52 PM
Insider Selling: Cytosorbents Corp (CTSO) CFO Sells 11,176 Shares of StockInsider Selling: Cytosorbents Corp (CTSO) CFO Sells 11,176 Shares of Stock
www.americanbankingnews.com - March 19 at 1:35 PM
CytoSorbents to Present at the 38th Annual Cowen Healthcare ConferenceCytoSorbents to Present at the 38th Annual Cowen Healthcare Conference
finance.yahoo.com - March 12 at 12:10 PM
Cytosorbents Corp (CTSO) Receives Average Recommendation of "Buy" from BrokeragesCytosorbents Corp (CTSO) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 11 at 1:38 AM
BRIEF-Cytosorbents Achieves Record Revenue And Product Sales Growth In 2017BRIEF-Cytosorbents Achieves Record Revenue And Product Sales Growth In 2017
www.reuters.com - March 10 at 5:58 PM
Cytosorbents (CTSO) Given a $12.00 Price Target by Maxim Group AnalystsCytosorbents (CTSO) Given a $12.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - March 10 at 5:10 PM
Cowen Reiterates "$9.00" Price Target for Cytosorbents (CTSO)Cowen Reiterates "$9.00" Price Target for Cytosorbents (CTSO)
www.americanbankingnews.com - March 10 at 12:30 AM
Cytosorbents (CTSO) PT Set at $14.00 by HC WainwrightCytosorbents (CTSO) PT Set at $14.00 by HC Wainwright
www.americanbankingnews.com - March 9 at 7:30 PM
Cytosorbents (CTSO) Releases  Earnings Results, Misses Expectations By $0.01 EPSCytosorbents (CTSO) Releases Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - March 9 at 12:38 AM
CytoSorbents Achieves Record Revenue and Product Sales Growth in 2017CytoSorbents Achieves Record Revenue and Product Sales Growth in 2017
finance.yahoo.com - March 8 at 6:05 PM
FY2017 Earnings Forecast for Cytosorbents Corp (CTSO) Issued By B. RileyFY2017 Earnings Forecast for Cytosorbents Corp (CTSO) Issued By B. Riley
www.americanbankingnews.com - March 7 at 7:26 AM
Head-To-Head Survey: Harvard Bioscience (HBIO) and Cytosorbents (CTSO)Head-To-Head Survey: Harvard Bioscience (HBIO) and Cytosorbents (CTSO)
www.americanbankingnews.com - March 7 at 1:16 AM
Zacks: Brokerages Expect Cytosorbents Corp (CTSO) to Post -$0.10 Earnings Per ShareZacks: Brokerages Expect Cytosorbents Corp (CTSO) to Post -$0.10 Earnings Per Share
www.americanbankingnews.com - March 4 at 1:32 PM
Cytosorbents (CTSO) to Release Earnings on ThursdayCytosorbents (CTSO) to Release Earnings on Thursday
www.americanbankingnews.com - March 2 at 9:30 AM
CytoSorbents to Report Fiscal 2017 Operating and Financial ResultsCytoSorbents to Report Fiscal 2017 Operating and Financial Results
finance.yahoo.com - March 1 at 8:40 AM
CytoSorbents to Participate at the BTIG Healthcare ConferenceCytoSorbents to Participate at the BTIG Healthcare Conference
finance.yahoo.com - February 26 at 8:44 AM
$4.57 Million in Sales Expected for Cytosorbents Corp (CTSO) This Quarter$4.57 Million in Sales Expected for Cytosorbents Corp (CTSO) This Quarter
www.americanbankingnews.com - February 17 at 2:28 AM
Zacks: Brokerages Expect Cytosorbents Corp (CTSO) Will Post Earnings of -$0.10 Per ShareZacks: Brokerages Expect Cytosorbents Corp (CTSO) Will Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - February 15 at 9:12 PM
CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia - PR Newswire (press release)CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia - PR Newswire (press release)
www.prnewswire.com - February 15 at 8:13 AM
CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in MalaysiaCytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia
finance.yahoo.com - February 15 at 8:13 AM
Cytosorbents Corp (CTSO) Given Average Recommendation of "Buy" by BrokeragesCytosorbents Corp (CTSO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 14 at 1:28 AM
Cytosorbents (CTSO) vs. Nanosphere (NSPH) Financial AnalysisCytosorbents (CTSO) vs. Nanosphere (NSPH) Financial Analysis
www.americanbankingnews.com - February 11 at 1:18 PM
Analyzing Pacific Biosciences of California (PACB) and Cytosorbents (CTSO)Analyzing Pacific Biosciences of California (PACB) and Cytosorbents (CTSO)
www.americanbankingnews.com - February 8 at 7:02 PM
CytoSorbents to Present at the 20th Annual BIO CEO & Investor ConferenceCytoSorbents to Present at the 20th Annual BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 9:32 AM
New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative ... - PR Newswire (press release)New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative ... - PR Newswire (press release)
www.prnewswire.com - February 3 at 4:05 PM
New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative CytoSorb® Blood PurificationNew Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative CytoSorb® Blood Purification
finance.yahoo.com - February 1 at 9:39 AM

SEC Filings

Cytosorbents (NASDAQ:CTSO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cytosorbents (NASDAQ:CTSO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cytosorbents (NASDAQ CTSO) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.